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Summary.-Organ-specific neoantigens (TA) shed from the tumours ofpatients with
metastatic breast or colon cancer and which had filtered into the urine were partially
purified by a combination of physicochemical methods and affinity chromatography.
TA activity of the isolated materials was monitored by the blocking Tube LAI assay.
Urinary protein was precipitated by 80% saturated ammonium sulphate. Albumin
was removed by affinity chromatography with blue Sepharose CL-6B. Affinity
columns of human IgG were prepared from sera of patients whose leucocytes were
LAI+ to the breast- or colon-cancer extracts. The anti-breast-TA affinity column
bound the TA in the urine of patients with metastatic breast cancer but not that of
patients with metastatic colon cancer. The TA in the urine of patients with metastatic
colon cancer was bound by the anti-colon-TA affinity column. Analysis by SDS
PAGE revealed that the isolates with and without TA activity were composed mostly
of urinary protein which had bound nonspecifically to the human IgG affinity
columns. With an affinity column of anti-NHS and Protein A, some of the con-
taminants were removed, toreveal SDS PAGEunique bands at about38,000 and 12,000
mol. wt in the isolate with breast-TA activity. Rabbit antisera, raised to the material
that had bound nonspecifically to the anti-breast-TA affinity column, were used as an
anti-nonspecific affinity column to remove the contaminants in the isolates from the
affinity columns of anti-breast TA and anti-colon TA. After passage through the
anti-nonspecific affinity column, the material that contained the putative breast or
colon cancer TA revealed a unique band at about 38,000-40,00 mol. wt and residual
fine bands at about25,000-30,000 mol. wt. Both the control material and materialwith
TA activity had similar bands at about25,000 and 50,000 mol. wt. The specific activity
ofthe putative colon or breast TAs, as measured by the blocking Tube LAI assay, was
increased from about 30 to 5000-10,000 u/mg, a 125-400-fold enrichment.
HISTOCOMPATIBILITY ANTIGENS have
been defined with alloantisera from im-
munized subjects. Alloantisera have been
invaluable in defining the polymorphism
of these antigens and monitoring their
purification. On the other hand, xenoanti-
bodies to the histocompatibility complex,
even to purified HLA antigens, have not
been reagents of great value in revealing
HLA allospecificity (Sanderson, 1977).
Likewise, detection of experimental or
human tumour-antigen epitopes by the
immunization of xenogeneic animals has
proved fraught with problems and few if
any tumour antigens to which the tumour-
bearing host responds have been defined.
In experimental tumour models the
existence of tumour-specific transplanta-
tion antigens was established on the basis
ofthe rejection oftransplantable tumours
in previously immunized syngeneic reci-
pients. Assays of cell-mediated and
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humoral antibody responses have been
used to monitor the isolation of tumour
antigens involved in the in vitro response
to the animal tumour cells (Baldwin &
Embleton, 1970). In our laboratory, the
isolation of a chemically induced tumour-
specific antigen (TSA) was monitored with
syngeneic tumour-immune serum and the
IgG from the tumour-immune serum was
used in affinity chromatography to isolate
the papain-solubilized TSA from tumour-
cell membranes (Thomson & Alexander,
1973; Thomson et al., 1973, 1976).
The principal evidence that human
tumoursexpressneoantigens hascomefrom
in vitro assays of cell-mediated and
humoral antibody responses to tumour
cells. Such assays have not been felt to be
sufficiently reliable to be used to monitor
the isolation of the tumour antigen (TA)
involved in the response. However, Halli-
day & Miller (1972) described a most
promising in vitro assay of human anti-
tumour immunity which is based on the
binding ofTA with the membrane ofsensi-
tized peripheral-blood leucocytes, which
inhibits the adherence ofthe leucocytes to
glass. The validity of leucocyte-adherence
inhibition (LAI) has been confirmed in
many laboratories (Holan et al., 1974;
Maluish & Holliday, 1975; Powell et al.,
1975; Burger et al., 1977; Leveson et al.,
1977; Russo et al., 1978; Shani et al.,
1978; Thomson, 1979).
A modified assay called the Tube LAI
was adopted in our laboratory (Grosser &
Thomson, 1975) and subsequently the
counting of the nonadherent leucocytes
was automatedbyimage analysis (Tataryn
et al., 1978; Thomson et al., 1979a).
Inhibition of the LAI response was used
to monitor the purification of human TAs
papain-solubilized from the membranes
ofhepatoma, malignant melanoma, breast
and colorectal cancer and the human TAs
were shown to be associated with 32-
microglobulin (Thomson et al., 1976,
1979b).
The present experiments were under-
taken to purify specific cancer TAs from
the urine of patients with metastatic
breast (Lopez & Thomson, 1977) or colon
cancer by affinity chromatography with
tumour-immune serum from patients
whose leucocytes were LAI+ (Grosser
et al., 1976; Marti et al., 1976). Success of
the method was judged by the enrichment
of the specific activity of the putative
colon or breast cancer TA when tested in
the blocking Tube LAI assay, and the
finding of polypeptide subunits unique to
the material with TA activity when
analysed by SDS PAGE.
MATERIALS AND METHODS
Doniors of leucocytes
Heparinized samples of blood were drawn
from patients with colon, breast or melanoma
cancer. Buffy-coat peripheral-blood leuco-
cytes (PBL) were processed for the Tube LAf
as described by Grosser & Thomson (1975).
Antigen-induced tube leucocyte-adherence
inhibition (Tube LAI)
The antigen-induced Tube LAI assay was
performed as described in detail by Grosser
& Thomson (1975). In most of the experi-
ments, nonadherent PBL were counted by
image analysis (Tataryn et al., 1978, 1979;
Thomson et al., 1979a). The results were
expressed as a nonadherence index (NAI)
(Grosser & Thomson, 1975) = [(A-B)/B] x 100,
where A is the number of nonadherent cells
in the presence ofthe specific antigen and B is
the number of nonadherent cells in the pres-
ence of the nonspecific antigen. To detect
LAI reactivity to colon cancer, the specific
antigen was an extract ofcolon cancer and the
nonspecific antigen was an extract of
squamous-cell lung cancer. To detect LAI
reactivity to breast cancer, the specific
antigen was an extract of breast cancer and
the nonspecific antigen was an extract of
malignant melanoma. LAI reactivity to
malignant melanoma was detected by revers-
ing the calculations with the extracts of
melanoma and breast cancer. NAIs ) 30
were considered positive and indicated anti-
tumourimmunity. NAIs < 30 were considered
negative because in previous studiesmorethan
95%0 of control subjects had NAIs < 30
(Flores et al., 1977; Lopez et al., 1978; Tataryn
et al., 1978, 1979).
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Blocking Tube LAI assay
In the Tube LAI assay, the number of
nonadherent leucocytes is affected by the
quantity of protein in the tubes. At about
100 pg/tube the number of nonadherent
leucocytes is optimal for counting. Too much
or too little protein causes too many or too
few leucocytes to be nonadherent for reliable
counting.
To detect antigen activity in small quanti-
ties of protein, the cells were preincubated
with the material, with the idea that the
specific effect of the antigen might be media-
ted during the incubation and, by washing
the cells free of unbound protein, the non-
specific effect of protein directly in the assay
would be eliminated, while maintaining the
desired specific effect. In subsequent experi-
ments, the preincubation of leucocytes with
the test or control material proved a valid
step (Grosser & Thomson, 1976; Marti et al.,
1976; Lopez & Thomson, 1977; Thomson
et al., 1978, 1979b). During preincubation
the leucocytes react with any sensitizing
antigen present, and when plated in the
standard assay the leucocytes will not react
again with the same specific antigen.
PBL were from patients with either malig-
nant melanoma, breast or colon cancer, and
reacted in the antigen-induced Tube LAI
assay against their respective cancer extracts.
A sample to be tested for TA activity was
diluted to the appropriate protein concentra-
tion in Medium 199 containing 20% foetal
calf serum, and 0.5 ml was preincubated with
a minimum of 1-3 x 107 leucocytes in 0 5 ml
ofMedium 199. The mixture was incubated at
37°C in a 5% C02 humidified atmosphere with
frequent agitation of the plastic tube. After
30 min the PBL were washed with 10 ml of
Medium 199 to remove the experimental
sample. The PBL were resuspended in
Medium 199 to 058 ml and then 041 ml of the
suspension was plated in each of the glass
test tubes with the specific and nonspecific
cancer extracts as described in the antigen-
induced Tube LAI assay. After 2 h incuba-
tion a sample of the nonadherent cells was
counted bythe computerized Tube LAI assay.
TA activity was present in the sample when
the LAI response was specifically and repro-
ducibly nullified. To compare antigenic activi-
ties at different stages of the purification, a
unit ofactivity was defined as the amount of
antigen needed to give an NAI <30 in the
blocking assay.
All samples that were tested in the blocking
assay were coded, and unknown to the two
individuals doing the LAI assay. Throughout
this study, one experimenter used the PBS
extracts ofcolon and squamous-cell lung can-
cer to test for LAI reactivity to colon cancer,
whilst the other used the PBS extracts of
breast cancer and malignant melanoma to
test for LAI reactivity to either breast cancer
or melanoma. Moreover, when the samples
were tested, a sample that might be expected
to block and a sample that should not block
(positive and negative contents) were inclu-
ded. Since abrogation of LAI by any sample
could be mediated by nonspecific and non-
immunologic substances, the samples which
blocked were then tested on LAI+ PBL from
patients with unrelated cancers, to test that
the sample did not affect the LAI of their
leucocytes.
Isolation of human TA Jrom urine
Physicochemical methods.-A 24h urine
sample from control subjects and patients
with metastatic colon or breast cancer were
collected in sterile containers and stored at
40C with 0 02% NaN3 and 15 ml I-OM Tris-
HCI buffer, pH 9. The urine was brought to
0-8 saturation with (NH4)2504 with constant
stirring and the resultant precipitate was
collected by centrifugation at 20,000 g for
10 min. The precipitate was suspended in a
minimal volume of PBS and dialysed twice
against 100 volumes of this buffer over 24 h
at 4°C. Insoluble material was removed by
centrifugation at 20,000 g for 10 min and the
supernatant was concentrated by ultra-
filtration on an Amicon PM10 membrane to
about 10-15 mg/ml. Albumin was removed
from the isolated urinary proteins by chroma-
tography with blue Sepharose CL-6B (Phar-
macia, Montreal) with all materials in 01M
sodium phosphate buffer, pH 7 0. The un-
retained material was concentrated and
dialysed against PBS at pH 7-3 (Lopez &
Thomson, 1977). This isolate of urinary pro-
tein was subjected to molecular-sieve chroma-
tography on a calibrated Sephadex G-150
column (2.5 x 60 cm) or applied to an affinity
column of human IgG.
Antisera used in the isolation ofTA from urine
Reactive human serum.-Sera from patients
with limited cancer of the breast whose
leucocytes were reactive in the Tube LAI
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assay were shown to "arm" normal leuco-
cytes to respond specifically in the LAI
assay (Marti et al., 1976) and this serum was
used in affinity chromatography. Similar
results were observed with sera from patients
with limited colon cancer. The affinity column
prepared with IgG from the serum of LAI+
breast-cancer patients was called an anti-
breast-TA affinity column, and the affinity
column prepared with the IgG from the serum
of LAI+ colon-cancer patients was called an
anti-colon-TA affinity column.
Anti-human whole serum.-Rabbits were
immunized with 1 ml ofnormal human serum
(NHS) in complete Freund's adjuvant. From
the resultant antiserum, antibodies directed
to membrane components were removed by
passage through an affinity column of AH-
Sepharase 4B to which papain-soluble human
liver-cell membrane was coupled.
Anti-nonspecific serum.-The urinary pro-
tein from the patients with metastatic colon,
or from breast cancer patients which bound
to the affinity column of anti-breast TA, was
used to immunize separate rabbits. Rabbits
were immunized i.m. at Days 1 and 4 with
250 jug of material mixed with 250 jig of
methylated bovine albumin and emulsified
with an equal volume of complete Freund's
adjuvant. The rabbits were boosted at 4
weeks with the material in incomplete
Freund's adjuvant and bled 6 and 7 weeks
after the priming injection.
Urinary protein from patients with meta-
static colon cancer wasisolatedbythephysico-
chemical methods described above and
linked to AH-Sepharose 4B (Cambiaso et al.,
1975). Through this affinity column was
separately passed the IgG from the antisera
of rabbits immunized with the bound colon
and breast urinary protein. The IgG which
bound to the column was eluted with 3M
KSCN. The eluted IgG had specificity for
colon and breast urinary protein that had
bound nonspecifically both to the anti-breast
TA column and to the anti-colon-TA affinity
column.
Affinity chromatography procedure.s
IgG from the different antisera was purified
by DEAE cellulose as described by Reif
(1969). The IgG was covalently coupled to
AH-Sepharose 4B (Cambiaso et al., 1975), and
thoroughly washed with 1-OM NaCl buffers
of high and low pH; then with 3M KSCN,
and finally with PBS at pH 7-3. The anti-
breast-TA and anti-colon-TA affinity
columns contained 70 and 40 ml of AH-
Sepharose 4B to which 2 and 1P5 g of IgG
were coupled, respectively.
Isolation of urinary TA by affinity
chromatography
Urinary protein isolated by physicochemi-
cal methods from patients with metastatic
colon or breast cancer was applied separately
to the anti-breast-TA affinity column. After
the unbound fraction was eluted with 10
column volumes of PBS at pH 7 3, the
column was prewashed with 1OM NaCl,
0dIM NaOH; glycine buffer (pH 9 0) to
remove nonspecifically adsorbed proteins
(Zoller & Matzku, 1976). The bound proteins
were then eluted with 3-OM KSCN, imme-
diately dialysed against BPS and concentra-
ted by ultrafiltration with a YM1O membrane
(Amicon). The unbound fraction was re-
turned to its original volume and the bound
fraction concentrated to about 1 mg/ml; and,
before storage at -40°C, both the unbound
and bound fractions were centrifuged at
100,000 g for 1 h. After thawing and before
being assayed the fractions were centrifuged
at 10,000 g for 10 min to remove denatured
materials.
The bound and unbound materials were
tested for TA activity, and their patterns on
SDS PAGE were analysed. The unbound
materials were then applied to the anti-
colon-TA affinity column and the unbound
and bound materials were similarly analysed.
Because the material isolated from either
the anti-breast-TA or anti-colon-TA affinity
columns had obvious protein contaminants,
either anti-NHS affinity chromatography or
the anti-nonspecific affinity columns were
used to remove the nonspecific urinary pro-
tein which had adhered to the anti-breast-TA
or anti-colon-TA affinity columns. Swollen
and washed Protein A linked to Sepharose
(1 ml) (Pharmacia) was placed at the bottom
of the anti-NHS and anti-nonspecific affinity
columns to remove IgG which may have bled
from the previous affinity columns.
Sodium-dodecyl sulphate (SDS)
polyacrylamide-gel electrophoresis (PAGE)
High-resolution SDS slab gels (0-75 mm
thick) were run under reducing conditions by
the discontinuous method ofLaemmli (1970),
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the running gel having an exponential
gradient of 5-20% polyacrylamide. The gels
were stained with 0.25% Coomassie blue,
4.5% methanol and 7.5% acetic acid. Radio-
iodination of the isolated urinary protein
was performed by the Chloramine T method,
with 1 mCi of 1251 and 50 ,g of protein. The
pattern of the radiolabelled proteins on SDS
PAGE was determined by autoradiography.
RESULTS
Partial purification of breast or colon
cancer TAs from urine
The partial purification of breast or
colon cancerTAsfrom the urine ofpatients
with metastatic breast or colon cancer
respectively was as outlined (Tables I and
II). TA activity was assayed by the block-
ing Tube LAI. An overall yield of 16-44%
wasobtainedwith anenrichmentofspecific
activity from 125- to 400-fold with 4
different preparations, the results of two
being detailed in Tables I and II.
After physicochemical isolation of TA
in urinary protein 80% or more of the TA
activity was recovered (Tables I and II).
PBL from patients with breast cancer had
their LAI activity abrogated by pre-
incubation with urinary protein from
patients with metastatic breast cancer,
but not from patients with metastatic
colon cancer (Table III). Similarly, LAI+
leukocytes from patients with colon can-
cer were blocked only by urinary protein
from patients with metastatic colon cancer
(Table III).
The urinary protein with TA activity
that did not bind to the blue Sepharose
CL-6B affinity columnwas electrophoresed
on SDS gels and stained with Coomassie
TABLE I.- Yield of breast TA from the urine ofpatients with metastatic breast cancer
Purification stage
Ammonium sulphate
Unbound fraction from blue Sepharose
CL-6B
Bound fraction from anti-breast-TA
affinity column
Unbound fraction from anti-NHS
Unbound fraction from anti-nonspecific
affinity column
Total
protein
(mg)
181t
Breast
TA units %
pg/unit* recovered Recovery
40 4525
94 25 3760
6-2 1.0 6200
1-7 05 3400
0-2 0-1 2000
Sp. act.t
(u/mg)
25
83 40 1-6
137 1000
75 2000
44 10,000 400
* The amount of protein required to specifically block LAI to an NAI of < 30.
t One unit of activity is defined as the amount of material which will reduce the LAI response to 30.
t Protein recovered from 2 separate 24h urine collections of a patient with terminal metastatic breast
cancer.
TABLE 11.- Yield of colon TA from the urine ofpatients with metastatic colon cancer
Purification stage
Ammonium sulphate
Unbound fraction from blue Sepharose
CL-6B
Unbound fraction from anti-breast-TA
affinity column
Bound fraction from anti-colon-TA
affinity column
Unbound fraction from anti-nonspecific
affinity column
Total
protein
(mg)
387*
Colon
TA units %
,ug/unit recovered Recovery
25 15,480
223 10
118 10
Sp. act.
(u/mg)
40
Enrich-
ment
(fold)
22,300 144 100 9-5
11,800
3-8 1-0 3,800
0.5 0-2 2,500
76 100 2-5
25 1000 25
16 5000 125
* Protein recovered from 3 separate 24h urine collections of a patient with terminal metastatic colonic
cancer.
Enrich-
ment
(fold)
40
80
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TABLE III.-Physicochemical isolation of TA from urinary protein from patients with
metastatic cancer (and one normal subject)
Preincubation of donor
leucocytes
Blue Sepharose CL-6B affinity
chromatography:
Unbound fraction of urinary
protein from patient with:
Breast ca
Prep. 1
Prep. 2
Colon ca
Breast ca
Prep. 1
Prep. 2
Colon ca
Prep. 1
Prep. 2
Prep. 3
Sephadex G-150 chromatography:
Urinary protein from patient with:
Breast ca
Fraction 1
Fraction 2
Fraction 3
Normal subject
Fraction 1
Fraction 2
Fraction 3
Breast ca
Fraction 3
Leucocyte
Donor NAI before
diagnosis incubation
Breast ca
Colon ca
Breast ca
Colon ca
Total
protein
concentration
ofblocking
material
(mg/,)
37 100
25
10
100
43
100
100
50
50
50
10
1
62
200
200
200
100
10
1
200
200
200
48
200
* An NAI > 30 was positive and indicated no blocking, whereas an NAI < 30 was negative
and indicated blocking. The specific and nonspecific cancer extracts were used at a concentra-
tion of 100 dig/tube.
blue. Multiple bands were visible (not
shown).
The isolated urinary protein was sub-
jected to molecular-sieve chromatography
on a calibrated column ofSephadex G-150,
and most of the protein eluted in a single
broad peak with the maximum OD280
at 48,000 mol. wt. The material that
eluted from the column was pooled into 3
fractions that corresponded approximately
to the excluded volume (Frac. 1), the
elution volume of aldolase (Frac. 2), and
ovalbumin (Frac. 3). The Sephadex G-150
Frac. 3 of the urinary protein from
patients with metastatic breast cancer had
specific blocking activity (Table III).
Urinary protein from patients with meta-
static colon cancer, isolated in a similar
manner, also had TA activity in Frac. 3
(results not shown). Moreover, Table III
shows that the material in Frac. 3 nullified
the LAI activity of leucocytes from
patients with colon or breast cancer in an
immunologically specific manner.
Urinary protein from 6 patients with
metastatic breast cancer and 5 patients
with metastatic colon cancer have been
similarly isolated and found to have
specific TA activity. Urinary protein from
2 patients without cancer had no blocking
activity. The urinary protein isolated
physicochemically and then by molecular-
NAI* after
blocking
-28
5
65
32
77
62
9
9
-24
15
45
68
63
8
19
14
45
71
66
88
59
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TABLE IV.-Isolation of TA from urinary protein of patients with metastatic breast or
colon cancer by affinity chromatography with Iga derived from serum of LAI+ breast
or colon cancer patients
Preincubation ofdonor
leucocytes
Affinity column of anti-breast TA:
Fractions and urinary protein from
patient with:
Breast ca
Unbound
Bound
Bound Prep. 1
Prep. 2
Unbound
Bound Prep. 1
Colon ca
Unbound
Bound
Bound
Normal subject
Unbound
Bound
Breast ca
Unbound
Bound
Colon ca
Unbound
Bound
Breast ca
Bound
Affinity column of anti-colon TA:
Fractions and urinary protein from
patients with:
Colon ca
Unbound
Bound Prep. 1
Prep. 2
Breast ca
Unbound
Bound
Colon ca
Bound Prep. 1
Prep. 2
Total
protein
concentration
Leucocyte ofblocking
Donor NAI before material
diagnosis incubation (mg/l)
Breast ca A
B
C
83
37
42
C 42
B
A
Colon ca
37
83
44
50
50
50
50
50
50
1-0
0*5
0-1
50
50
50
200
200
50
50
50
50
Malignant
Melanoma
Colon ca A
111
s0
41
B 79
C 61
Breast ca 55
60
50
20
10
1
0-1
25
10
1-0
0*5
50
50
50
50
* The specific and nonspecific cancer extracts were used at , 100,g/tube. An NAI value < 30
is negative and indicates that the LAI was negated by the preincubation.
NAI* after
blocking
109
-15
23
7
55
-11
23
3
62
43
37
53
51
73
80
65
-29
67
63
67
21
1
45
47
-16
-8
9
48
67
65
71
58
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sieve chromatography from a control
subject and a patient with metastatic
breast cancer showed no unique differences
by SDS PAGE.
Affinity chromatography with IgG from
LAI+ patients with cancer of the breast
(anti-breast TA) or colon (anti-colon TA)
Anti-breast TA. Isolated urinary pro-
tein from patients with either metastatic
breast or colon cancer was applied separ-
ately to the anti-breast-TAaffinitycolumn.
The unbound, bound and eluted fractions
were then assayed for TA activity (Table
IV). The bound and eluted fraction of
urinary protein from the patients with
metastatic breast cancer (but not from the
controls) negated the LAI activity of
leucocytes from patients with breast
cancer. Moreover, LAI+ leucocytes from
patients with colon cancer or malignant
melanoma showed LAI activity in the
presence of the isolate that blocked the
LAI activity of leucocytes from breast-
cancer patients (Table IV). The unbound
fraction of urinary protein from patients
with cancer of the colon did not block
LAI+ leucocytes from breast-cancer pa-
tients, whereas the same unbound urinary
protein blocked the LAI reactivity of
leucocytes from colon-cancer patients
(Table IV). Affinity chromatography with
the anti-breast-TA affinity column in-
creased the specific activity of the breast
TA about 25-fold (Table I), and had no
effect on the specific activity of the colon
TA (Table II).
Anti-colon TA. The urinary protein
which did not bind to the anti-breast-TA
affinity column was applied to the anti-
colon-TA affinity column. The urinary
protein from patients with metastatic
colon cancer that bound and was eluted,
was enriched for colon-TA activity from
10- to 30-fold. Table II shows that the
specific activity of the colon TA was in-
creased from 100 to 1000 u/mg, a 10-fold
enrichment. The isolate blocked LAI+
leucocytes from colon-cancer patients in an
immunologically specific manner (Table
IV). The isolate of colon urinary protein
did not inhibit the LAI activity of leuco-
cytes from breast-cancer patients, nor did
the bound and eluted material from
breast urinary protein from the anti-colon-
TA affinity column alter the LAI activity
of PBL from colonic-cancer patients
(Table IV).
SDS PAGE of the isolates of the
urinary protein from either control sub-
jects, metastatic breast or colon cancer
patients revealed fewer bands; however,
the isolate from the urinary protein from
patients with metastatic breast or colon
cancer showed no difference from the
isolates from the controls (not shown) in
spite ofthe use of O -OM NaCl, 0dIM NaOH:
glycine buffer (pH 9.0) to remove the
proteins that had adhered nonspecifically
to the affinity column before elution with
3*OM KSCN.
Affinity chromatography with anti-NATHS and
protein A
The binding of undesired urinary pro-
tein was greater than the specific binding
of the breast TA to the anti-breast-TA
affinity column. To remove the unwanted
protein contaminants, the isolates from
the urinary protein from normal subjects,
breast and colon-cancer patients were
passed through an affinity column of
rabbit anti-NHS and Protein A which
yielded a 2-fold enrichment of breast TA
(Table I). The isolate from the urine from
patients with metastatic breast cancer
blocked LAI+ leucocytes from patients
with breast cancer, whereas similarisolates
from normal subjects and patients with
metastatic colon cancer had no effect on
LAI. Furthermore, theisolate that blocked
LAI+ leucocytes from patients with breast
cancer did not block the LAI+ of leuco-
cytes from patients with other cancers
(Table V). Hence, the blocking was
specific.
The SDS PACGE pattern of the isolate
from the breast or colon cancer urinary
protein that did not bind to the anti-NHS
and Protein A affinity column is shown in
Fig. 1. Both isolates show 2 bands at a
mol. wt of 25,000 and 3 bands at
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TABLE V.-Breast cancer TA isolated from urinary protein by anti-breast-TA affinity
chromatography and further purified by affinity chromatography with anti-lVHS and
protein A
Total
protein
concentration
of blocking
Preincubation of dlonor
leucocytes
Bound samples from anti-breast-TA
affinity column:
Affinity column of anti-NHS an(d
protein A fractions of:
Metastatic breast ca
Unboundl Prep. 1
Prep. 2
AMetastatic colon ca
Unbound
Normal subjects
Unbound
Metastatic breast ca
Unboundl
Unboun(d
Donor NAI before material NAI after
diagnosis incubation (mg/I) blocking
36
35
44
50
50
1-0
0 5
01
0-01
50
Breast ca A
B
C
A 36
B 35 100
Malignant
melanoma
Colon ca
38
61
50
.50
0
18
12
17
92
74
33
43
57
78
50,000. However, the isolate from the
breast-cancer urinary protein has an
intense band at a mol. wt of - 12,000, in
contrast to the isolate from the colon-
cancer urinary protein, and a unique band
at - 38,000 (Fig. 1).
The isolates of the breast-and colon-
cancer urinary protein from the anti-NHS
affinity column were radiolabelled with
1251 and run on the SDS slab gels. Fig. 2
shows the autoradiographs of the isolate
from the breast-cancer urinary protein
before and after incubation and clearing
with Protein A on fixed bacteria (Kessler,
1975) and the isolate from the colon
cancer urinary protein. The isolate from
the breast-cancer urinary protein has a
unique band at a mol. wt of - 38,000.
The band at - 12,000 mol. wt is more
intense in the isolate from breast than
colon cancer urinary protein. In compari-
son, Fig. 2 shows an autoradiograph of
papain-soluble breast-cancer membrane
material purified by a horse anti-human-:2
microglobulin affinity column (Thomson
et al., 1976, 1979b). This material also
blocked specifically the LAI reactivity of
leucocytes from breast cancer patients and
did not alter that from patients with
colon cancer or melanoma.
The anti-NHS and Protein A affinity
column removed some of the protein
contaminates from the isolates recovered
from the anti-breast-TA affinity column
with a 2-fold increase in specific activity
of the breast TA. However, on SDS
PAGE a number ofintense, common bands
remained in the materials with andwithout
breast-TA activity.
Affinity chromatography with anti-
nonspecific sera
Although the TAs in the urineofpatients
with metastatic cancer could be isolated
by an affinity column of tumour-specific
IgG, the isolates were clearly contamina-
ted by other species of urinary protein.
The anti-NHS and Protein A affinity
column did not remove enough of the
contaminants from the isolates, so another
approach was made.
Antiserum to the nonspecific proteins
eluted from the anti-breast affinity column
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A B C
FiG. I.-SDS PAGE analysis of the bound
and eluted isolates of urinary protein from
the anti-breast-TA affinity column that
were then passed through the anti-NHS
and Protein-A affinity column A mol. wt
standards; B, urinary protein from patient
with metastatic colon cancer; C, urinary
protein from patient with metastatic breast
cancer. Triangles point to bands in the
isolate from breast urinary protein but
which are either absent or in minimal
amounts in the isolate from colon urinary
protein.
4
was prepared as described in Materials and
Methods. With this antiserum an anti-
nonspecific affinity column was prepared.
The possibility that the antiserum might
react with the TA in the urine was con-
sidered.
The bound andeluted samples ofurinary
protein from patients with metastatic
breast or colon cancer from the anti-
breast-TA affinity column were applied to
the anti-nonspecific affinity column. Table
VI shows that the unbound isolate from
urinary protein from patients with meta-
static breast cancer negated the LAI of
leucocytes from patients with breast
cancer, whereas the unbound isolate from
the urinary protein ofpatients with meta-
static colon cancer did not block. In
contrast, LAI+ leucocytes from patients
with colon cancer reacted in the presence
7
68000_-
43,000-bi0...
25q00OO-.r'
12,400b'
.....
A B C D
FIG. 2. SDS PAGE analysis (autoradio-
grams) of 1251-labelled isolates of the
following: A, papain-soluble material from
the membranes of breast cancer that were
bound and eluted from a horse anti-
human-fl2-microglobulin affinity column;
B, bound and eluted isolate of urinary pro-
tein from a patient with metastatic breast
cancer from the anti-breast-TA affinity
column that was passed through the
anti-NHS and Protein-A affinity column;
C, same material cleared with Protein
A of whole fixed Staphylococcus; D, bound
and eluted isolate of urinary protein from
a patient with metastatic colon cancer from
the anti-breast-TA affinity column that was
passed through the anti-NHS and Protein-
A affinity column.
of the unbound isolates from the breast-
and colon-cancer urinary protein (Table
VI). Similarly, the bound and eluted
urinary protein from the anti-colon-TA
affinity column were applied to the anti-
nonspecific affinity column. Table VI
shows that the unbound isolate from colon
urinary protein nullified LAI in an immu-
nologically specific manner. The anti-
nonspecific affinity column increased the
TA-specific activity about 5-fold (Tables
I and II).
Fifty-jig samples of the 4 isolates from
the anti-breast-TA and anti-colon-TA
affinity column were labelled with 125I.
The 1251-labelled isolates were applied
separately to the anti-nonspecific affinity
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TABLE VI. Breast- or colon-cancer TA isolated from urinary protein by anti-breast-TA
or anti-colon-TA affinity chromatography and further purified by anti-nonspecific
affinity chromatography
Preincubation of donor
leucocytes
Bound samples from anti-breast-TA
affinity column:
Affinity column of anti-nonspecific:
Unbound fractions of:
Metastatic breast ca
Total
protein
concentration
of blocking
Donor NAI before material
diagnosis incubation (mg/l)
Prep. 1 Breast ca A 77
B 108
Mletastatic colon ca
Metastatic breast ca Colon ca
MNetastatic colon ca
Bound samples from anti-colon-TA
affinity column:
Affinity column of anti-nonspecific:
Unbound fractions of:
Mletastatie colon ca
Prep. I C'olon ca
Prep. 2
AMetastatic colon ca Bieast ea
Metastatic breast ca
77
68
60
41
46
80
10
1.0
0 5
0-1
0*05
0 05
25
25
25
10
1-0
0-1
0-05
10
1.0
0-5
0o2
0-1
25
25
column and the unbound material was
collected and concentrated. The 125I
labelled isolates were electrophoresed on
SDS gels and the patterns were auto-
radiographed.
The isolate from the breast urinary
protein from the anti-breast TA affinity
column shows a heavy band at 38,000
mol. wt that is not observed in the isolate
from the colon urinary protein from the
same affinity column (Fig. 3). After pas-
sage through the anti-nonspecific affinity
column, the 1251-labelled isolate from the
breast urinary protein continued to show
a strong band at a mol. wt ofabout 38,000.
Three finer bands at 25,000-30,000
mol. wt were seen, and at least one ofthese
bands appeared in the isolate from the
colon urinary protein after passage
through the anti-nonspecific affinity
column. Isolates from both colon and
breast urinary protein show a band at
50,000 mol. wt that was not removed by
the anti-nonspecific affinity column.
An autoradiograph of the isolate from
the colon-cancer urinary protein from
the anti-colon-TA affinity column shows
a band at , 40,000 mol. wt (Fig. 4),
whereas the isolate from the colon urinary
protein from the anti-breast-TA affinity
column lacked a band at this mol. wt
(Figs 2 and 3). After passage through the
anti-nonspecific affinity column, the isolate
from the colon urinary protein from the
anti-colon-TA affinity column continued
to have a heavy band at - 40,000 mol. wt.
NAI after
blocking
-15
-28
-16
-22
45
:35
125
87
41
-:3
2
16
48
-14
15
12
4
40)
67
66
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FIG. 3. SDS PAGE analysis (autoradio-
grams) of 1251-labelled isolate containing
breast TA activity and control material. A,
urinary protein from patient with meta-
static breast cancer bound and eluted from
the anti-breast-TA-affinity column; B,
same material. applied and unbound on the
anti-nonspecific affinity column; C, urinary
protein from patient witli metastatic colon
cancer bound and elutedl from the anti-
breast-TA affinity column; D, same
material applie(l an(d unbound from the
anti-nonspecific affinity column.
The heavy band at 25,000 mol. wt was
removed, although 4 fine bands remained
at 25,000-30,000 mol. wt. A faint band at
12,000 mol. wt is also present.
In comparison, an autoradiograph ofthe
isolate from the breast urinary protein
from the anti-colon TA affinity column is
shown in Fig. 5. A heavy band is present
at 25,000 mol. wt with faint bands at
- 50,000 and 12,000 mol. wt. However,
the isolate from the breast urinary
protein from the anti-colon-TA affinity
column lacked a band at , 40,000 vol. wt
(Fig. 5). After passage of the breast
urinary protein from the anti-colon-TA
affinity column through the anti-non-
specific affinity column, no band at
40,000 mol. wt was seen, although a
band at 50,000 mol. wvt and a faint band
at - 25,000 mol. wt remained.
DISCUSSION
Since the TA is denatured by SDS
PAGE, there is no way to determine
68,000*
1234000.,_l19~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~..........i>o
..: .. :: ..... t _..l|
FmG. 4..SDS PAGE autoradiograms of 125
labelled material from an isolate containing
colon-TA activity. A, urinary protein from
patient with metastatic colon caneri un-
bound from the anti-breast-TA affinity
column and bound and eluted from the
anti-colon-TA affinity column; B, same
material applied and unbound on the anti-
nonspecific affinity column.
which, if any, of the bands visualized in
the gels carries the TA epitope. Previously
we have shown that human TAs papain-
solubilized from the membranes of hepa-
toma, malignant melanoma, breast and
colon cancer were linked tot2-micro-
globulin (Thomson et at., 1976, 1979b;
Thomson, 1979). In this study, the
material with specific TA activity had a
12,000-mol.-wt subunit which became
fainter with purification, which suggests
that the association between P2-micro-
globulin and the molecule which carries
the TA epitope was partially ruptured
during isolation. Histocompatibility anti-
gens isolated from urine are reported to
show dissociation of the heavy chain and
32-microglobulin (Bernier et at., 1974).
Human cancers express organ-type-
specific neoantigens which are immuno-
genic to the host bearing the cancer. The
same antigens exist in some premalignant
lesions such as colon adenomas (Tataryn
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68,000"-
43,000- *-
25,0001 -
1 2,400-*
FIG. 5.-SDS PAGE autoradiogram of
urinary protein from patient with meta-
static breast cancer unbound from the
anti-breast-TA affinity column and bound
and eluted from the anti-colon-TA affinity
column.
et al., 1979) and in tissues of organs that
display dysplastic changes of epithelium
which may or may not be premalignant,
such as papillomatosis and fibrocystic
disease of the breast (Flores et al., 1977;
Lopez et al., 1978; O'Connor et al., 1978;
Thomson et al., 1979; Sanner et al., 1979)
and chronic atrophic gastritis (Tataryn
et al., 1979). The epitope of the organ-
specific neoantigen has not been detected
in the tissues of normal organs (Grosser
& Thomson, 1975; O'Connor et al., 1978;
Thomson et al., 1979b; Tataryn et al.,
1979). The organ-specific neoantigen is
probably not synthesized de novo, but
the mutational process involved in the
genesis of the cancer or dysplastic cell
may induce some rearrangement of a cell-
surface protein of the normal cell. The
nature of the change in the cell-surface
protein is unknown, but might represent
exposure of cryptic sites or structural
changes. The question which cell-surface
protein has an organ-specific neoantigen
epitope that becomes immunogenic will
probably not be answered until the mole-
cule is purified and characterized.
This work was supported by grants from the
Medical Research Council of Canada, The Cancer
Research Society Inc. of Montreal and The National
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